NAD+ Nasal Spray

NAD+ nasal spray is a compounded formulation intended for intranasal administration. Research for broad wellness and performance claims is limited, and treatment should follow an individualized provider assessment.

• When a provider discusses the evidence, uncertainties, and alternatives with the patient.
• When the formulation and route are clinically appropriate for the individual.

The nasal route is intended to deliver the compounded ingredient across nasal tissues. Absorption and effects may vary, and broad benefit claims are not established.

• Review of nasal conditions and current medicines.
• Instructions specific to the dispensed product.
• Monitoring for local irritation or other symptoms.

Intranasal use as directed by the prescriber. Use only according to the exact instructions supplied by your prescribing provider and dispensing pharmacy.

The IV Code does not publish generalized dosing because instructions depend on the individual, prescription, and dispensed formulation.

• People with significant nasal disease, recent nasal surgery, ingredient sensitivities, pregnancy, or breastfeeding need individualized guidance.

Compounded medications are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality in the same manner as FDA-approved drugs. A licensed provider evaluates each patient; a prescription is not guaranteed. Compounded treatment should be prescribed only when the provider determines it is appropriate for the individual patient and applicable legal requirements are satisfied. Cost or preference alone does not establish medical necessity for compounding.

A compounded medication is not the same thing as an FDA-approved generic drug.